Amgen's Options: A Look at What the Big Money Is Thinking
Amgen's Options: A Look at What the Big Money Is Thinking
Deep-pocketed investors have adopted a bearish approach towards Amgen (NASDAQ:AMGN), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMGN usually suggests something big is about to happen.
资金雄厚的投资者们对安进（纳斯达克：AMGN）采取了看淡的策略，市场参与者不应忽视这一点。本周财经网站Benzinga对公开期权记录的追踪揭示了这一重大举措。这些投资者的身份仍然是未知的，但在AMGN中出现这样大规模的举动通常意味着即将发生重大事件。
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Amgen. This level of activity is out of the ordinary.
我们从观察到的Amgen期权扫描仪突出的10项非凡期权活动中获得了这些信息。这种活动水平是非同寻常的。
The general mood among these heavyweight investors is divided, with 40% leaning bullish and 60% bearish. Among these notable options, 6 are puts, totaling $259,893, and 4 are calls, amounting to $155,093.
这些重量级投资者中普遍情绪不一，40%看好，60%看淡。在这些显要的期权中，有6个看跌，总计$259,893，4个看涨，总计$155,093。
Expected Price Movements
预期价格波动
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $295.0 to $360.0 for Amgen during the past quarter.
分析这些合同的成交量和持仓量，似乎大户已经在过去一季度红范围内的$295.0至$360.0之间关注Amgen的价格窗口。
Volume & Open Interest Trends
成交量和未平仓量趋势
In terms of liquidity and interest, the mean open interest for Amgen options trades today is 539.75 with a total volume of 1,599.00.
在流动性和利益方面，今天Amgen期权交易的平均持仓量为539.75，总成交量为1,599.00。
In the following chart, we are able to follow the development of volume and open interest of call and put options for Amgen's big money trades within a strike price range of $295.0 to $360.0 over the last 30 days.
在下面的图表中，我们可以追踪Amgen重要交易的看涨和看跌期权的成交量和持仓量在$295.0至$360.0的行权价格范围内在过去30天内的发展。
Amgen Call and Put Volume: 30-Day Overview
安进看涨和看跌成交量：30天概述
Largest Options Trades Observed:
观察到的最大期权交易：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | PUT | SWEEP | BEARISH | 08/09/24 | $8.35 | $7.85 | $8.35 | $327.50 | $70.9K | 62 | 90 |
| AMGN | PUT | SWEEP | BEARISH | 10/18/24 | $8.8 | $8.2 | $8.8 | $315.00 | $62.4K | 495 | 77 |
| AMGN | CALL | TRADE | BULLISH | 01/17/25 | $50.15 | $49.25 | $50.15 | $300.00 | $50.1K | 1.5K | 0 |
| AMGN | CALL | TRADE | BULLISH | 10/18/24 | $7.65 | $7.55 | $7.65 | $360.00 | $48.1K | 397 | 343 |
| AMGN | PUT | TRADE | BULLISH | 01/17/25 | $19.35 | $18.55 | $18.55 | $310.00 | $33.3K | 1.0K | 20 |
| 标的 | 看跌/看涨 | 交易类型 | 情绪 | 到期日 | 卖盘 | 买盘 | 价格 | 执行价格 | 总交易价格 | 未平仓合约数量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | 看跌 | SWEEP | 看淡 | 08/09/24 | $8.35 | $7.85 | $8.35 | $327.50 | $70.9千 | 62 | 90 |
| AMGN | 看跌 | SWEEP | 看淡 | 10/18/24 | $ 8.8 | $8.2 | $ 8.8 | $315.00 | $62.4千美元 | 495 | 77 |
| AMGN | 看涨 | 交易 | 看好 | 01/17/25 | $50.15 | $49.25 | $50.15 | $ 300.00 | $50.1K | 1.5K | 0 |
| AMGN | 看涨 | 交易 | 看好 | 10/18/24 | $7.65 | $7.55 | $7.65 | $360.00 | $48.1K | 397 | 343 |
| AMGN | 看跌 | 交易 | 看好 | 01/17/25 | $19.35 | $18.55 | $18.55 | $ 310.00 | $33.3K | 1.0K | 20 |
About Amgen
关于安进
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
安进是生物技术制药领域的领导者。旗舰药物包括增加红细胞计数的艾普毕与阿拉尼许、增强免疫系统的奈帕姆和奈乌细胞移植因子、以及针对炎症性疾病的恩布瑞尔和欧特兹拉。安进在2006年推出了首个癌症治疗药物Vectibix，并推出了增强骨密度的药物Prolia/Xgeva（于2010年获批）和Evenity（于2019年获批）。对Onyx的收购增强了该公司在治疗肿瘤领域的药物组合，其中包括Kyprolis。最近推出的药物包括Repatha（降低胆固醇）、Aimovig（缓解偏头痛）、Lumakras（治疗肺癌）以及Tezspire（治疗哮喘）。2023年Horizon收购带来了几种罕见疾病药物，其中包括治疗甲状腺眼病的Tepezza。安进还拥有不断增长的生物类似物组合。
Following our analysis of the options activities associated with Amgen, we pivot to a closer look at the company's own performance.
在我们分析与安进相关的期权活动之后，我们将转向更仔细地研究公司自身的表现。
Current Position of Amgen
安进的当前位置
- With a volume of 1,143,672, the price of AMGN is down -0.98% at $332.25.
- RSI indicators hint that the underlying stock may be approaching overbought.
- Next earnings are expected to be released in 4 days.
- 伴随着1,143,672的成交量，AMGN的价格下跌-0.98%，为$332.25。
- RSI指标暗示该股票可能要超买了。
- 下一季度收益预计将在4天内发布。
What Analysts Are Saying About Amgen
分析师对安进的评论
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $303.0.
在过去30天中，总共有1名专业分析师发表了他们对这只股票的看法，设定了平均目标价为$303.0。
- An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on Amgen, which currently sits at a price target of $303.
- 摩根士丹利的一位分析师决定维持对安进的中性评级，目标股价目前为303美元。
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Amgen options trades with real-time alerts from Benzinga Pro.
期权交易具有更高的风险和潜在回报。精明的交易者通过不断学习、调整策略、监控多个因子和密切关注市场走势来管理这些风险。通过Benzinga Pro的实时提醒了解最新的安进期权交易。